The Food and Drug Administration (FDA) has given people with multiple sclerosis some hope.On Wednesday, FDA officials announced the agency has approved a new drug for Multiple Sclerosis Treatment as well as primary progressive MS (PPMS).It’s the first drug approved for treatment of PPMS.The drug, Ocrevus (ocrelizumab), is an intravenous infusion given by a medical professional.The approval is especially good news for those with progressive types of MS who have not found a drug that has worked to reduce flares, improve symptoms, or slow disease progression.
According to the National Multiple Sclerosis Society, 2.3 million people worldwide are living with the disease.Now, for the first time, people with PPMS may benefit from what officials at Roche Pharmaceuticals have called a medical breakthrough.In a large phase III trial, Ocrevus was shown to significantly slow the progression of physical disability in people with PPMS. It was also successful in two large studies at reducing attacks in people with relapsing MS (RMS), according to Roche.
How the Multiple Sclerosis Treatment drug works
MS hits everyone differently, with an array of symptoms and possible progressions.Its unique characteristics make finding remedies a challenge.Some people with MS may respond to one of the injectable disease modifying drugs (DMD) on the market.